Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Biotech Active Runners: Novavax (NASDAQ:NVAX), VIVUS (NASDAQ:VVUS), Rexahn Pharmaceuticals (NYSEMKT:RNN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Novavax, Inc. (NASDAQ:NVAX), announced on Thursday that the Biomedical Advanced Research and Development authority extended the base period of performance of a contract with the pharmaceutical company for its recombinant seasonal and pandemic influenza vaccines. Novavax, Inc. (NASDAQ:NVAX) stock performance was 1.27% in last session and finished the day at $6.38. Traded volume was 13,436,282 million shares in the last session and the average volume … Continue reading Biotech Active Runners: Novavax (NASDAQ:NVAX), VIVUS (NASDAQ:VVUS), Rexahn Pharmaceuticals (NYSEMKT:RNN), Ariad Pharmaceuticals (NASDAQ:ARIA)

VIVUS Inc. (NASDAQ:VVUS) stock was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $15.00. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 1.00% in last session and finished the day at $6.09. Traded volume was 5,364,675 million shares in the last session and the average volume … Continue reading Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -3.34% in last session and finished the day at $8.69. Traded volume was 1,200.00 shares in the last session and the average volume of the stock remained 26.48 million shares. The beta of the stock remained 1.64. Ariad Pharmaceuticals, Inc. … Continue reading Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Rexahn Pharmaceuticals (NYSEMKT:RNN), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (NASDAQ: MNKD) is a small company based in Valencia, California, poised to launch its FDA approved drug, Afrezza, as treatment indications for both Type 1 and Type 2 diabetes. Despite near unanimous backing from experts at the Advisory Committee (ADCOM) and the medical community, Mr. Market is still pessimistic on the company. MannKind Corporation (NASDAQ:MNKD) stock performance was -2.50% in last session and finished the … Continue reading Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY)

Priceline Group Inc (NASDAQ:PCLN) Director Jeffery H. Boyd sold 3,000 shares of Priceline Group stock on the open market in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $1,228.00, for a total transaction of $3,684,000.00. Following the sale, the director now directly owns 194,125 shares of the company’s stock, valued at approximately $238,385,500. Priceline Group Inc (NASDAQ:PCLN) stock … Continue reading Trending Stocks – Priceline (NASDAQ:PCLN) , Ariad Pharmaceuticals (NASDAQ:ARIA) , Hi-Crush Partners (NYSE:HCLP) , Rackspace (NYSE:RAX) , SMFG)